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Adiponectin has been shown to stimulate fatty
acid oxidation and enhance insulin sensitivity
through the activation of AMP-activated protein
kinase (AMPK) in the peripheral tissues. The ef-
fects of adiponectin in the central nervous sys-
tem, however, are still poorly understood. Here,
we show that adiponectin enhances AMPK
activity in the arcuate hypothalamus (ARH) via
its receptor AdipoR1 to stimulate food intake;
this stimulation of food intake by adiponectin
was attenuated by dominant-negative AMPK
expression in the ARH. Moreover, adiponectin
also decreased energy expenditure. Adiponec-
tin-deficient mice showed decreased AMPK
phosphorylation in the ARH, decreased food in-
take, and increased energy expenditure, exhib-
iting resistance to high-fat-diet-induced obe-
sity. Serum and cerebrospinal fluid levels of
adiponectin and expression of AdipoR1 in theARH were increased during fasting and de-
creased after refeeding. We conclude that adi-
ponectin stimulates food intake and decreases
energy expenditure during fasting through its
effects in the central nervous system.
INTRODUCTION
White adipose tissue (WAT) is a major site of energy stor-
age and plays an important role in energy homeostasis.
It is also recognized as an important endocrine organ
that secretes a number of biologically active adipokines
(Kahn, 2000). Adiponectin, an adipokine secreted exclu-
sively by the WAT, is present at relatively high concentra-
tions in the circulation (Kadowaki, et al., 2006; Scherer,
2006). Adiponectin has been shown to increase the sensi-
tivity of peripheral tissues to insulin, and it has been sug-
gested that the decreased circulating levels of adiponectin
in obesity and type 2 diabetes may contribute to the insulin
resistance that characterizes both conditions (Berg et al.,
2001; Fruebis et al., 2001; Yamauchi et al., 2001; Kado-
waki, et al., 2006; Scherer, 2006). In humans, plasmaCell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 55
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related with the body weight, body fat mass, and degree of
insulin resistance, and weight reduction in obese individ-
uals has been shown to be accompanied by an increase
in plasma adiponectin concentrations (Kadowaki, et al.,
2006; Scherer, 2006). Administration of recombinant adi-
ponectin to rodents increases glucose uptake and fat
oxidation in muscle, reduces hepatic glucose production,
and improves whole-body insulin sensitivity (Berg et al.,
2001; Fruebis et al., 2001; Yamauchi et al., 2001). Adipo-
nectin-deficient (adipo/) mice exhibit insulin resistance
and glucose intolerance (Kubota et al., 2002; Nawrocki
et al., 2006).
Adiponectin structurally belongs to the collagen super-
family and shares homologies with the collagens, comple-
ment factors, and TNFa (Scherer et al., 1995). Monomeric
subunits oligomerize to form trimers that further associate
through disulfide bonds within the collagenous domain to
form hexamers and the high-molecular-weight (HMW) 12-
to 18-mers (Pajvani et al., 2003). The HMW multimers are
present in abundance in human serum and are thought to
be among the more active forms of the protein (Kadowaki,
et al., 2006; Scherer, 2006).
AMP-activated protein kinase (AMPK) plays a key role in
the regulation of energy homeostasis (Hardie, 2004; Carl-
ing, 2005; Luo, et al., 2005) and has recently been found
to mediate the stimulation of fatty acid oxidation induced
by leptin (Minokoshi et al., 2002) and adiponectin (Yamau-
chi et al., 2002) in skeletal muscle. Remarkably, AMPK
also appears to be closely involved in energy homeostasis
in the central nervous system (CNS) (Hardie, 2004; Carl-
ing, 2005; Kim and Lee, 2005). Decrease in AMPK activity
in the hypothalamus has been suggested to lead to re-
duced food intake and increased energy expenditure
(Hardie, 2004; Carling, 2005; Kim and Lee, 2005). Sup-
pression of AMPK activity seems to mediate the decrease
in food intake induced by leptin because expression of ac-
tive mutants of AMPK and dominant-negative inhibitory
mutants of AMPK in the hypothalamus stimulate and in-
hibit food intake, respectively (Minokoshi et al., 2004).
In addition to its peripheral actions on the liver and skel-
etal muscle, including activation of AMPK and enhance-
ment of whole-body insulin sensitivity, adiponectin has
also been reported to have central actions (Qi et al., 2004).
Adiponectin increases oxygen consumption and thermo-
genesis, which lead to weight loss, and the degree of
weight loss is similar to that induced by leptin in C57BL/
6 or ob/ob mice, despite having no effect on food intake
(Qi et al., 2004). Recently, however, it was reported that
adiponectin is undetectable in human cerebrospinal fluid
(CSF) and that it does not cross the blood-brain barrier
(BBB), although both isoforms of the adiponectin recep-
tor, AdipoR1 and AdipoR2 (Yamauchi et al., 2003), have
been demonstrated to be expressed in brain endothelial
cells (Spranger et al., 2006). Thus, the physiological role
of adiponectin in the CNS remains controversial.
In this study, we demonstrate the presence of adipo-
nectin in the CSF and also show that adiponectin enters
the CSF from the circulation; interestingly, only trimers and56 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.hexamers were found, and unlike in the serum, HMW mul-
timers could not be detected in the CSF. In addition, we
show that adiponectin enhances AMPK activity in the
arcuate hypothalamus (ARH) via its receptor AdipoR1
and stimulates food intake, and also that this stimulation
of food intake by adiponectin is attenuated by dominant-
negative AMPK expression in the ARH. Moreover, adipo-
nectin also decreases the energy consumption. Consis-
tent with these findings, adipo/ mice showed decreased
AMPK phosphorylation in the ARH. These mice also
showed reduced food intake and increased energy ex-
penditure, thereby exhibiting resistance to high-fat diet
(HFD)-induced obesity. Taken together, these findings in-
dicate a physiological role of adiponectin in the regulation
of food intake via regulation of AMPK activity in the ARH.
RESULTS
Adiponectin Receptors Are Present
in the Hypothalamus, and Adiponectin Enters
the CSF from the Circulation
Both the major isoforms of the adiponectin receptor,
AdipoR1 and AdipoR2 (Yamauchi et al., 2003), were found
to be abundantly expressed in the hypothalamus, and their
expression levels were comparable to those in the liver
(Figure 1A). In situ hybridization analysis using antisense
probes revealed expression of AdipoR1 and AdipoR2 as
well as the leptin receptor in the ARH (Figure 1B), whereas
no receptor expression was detected in the hypothalamus
when sense probes for AdipoR1 and AdipoR2 were used
(see Figure S1A in the Supplemental Data available with
this article online). Expression of AdipoR1 and AdipoR2
was also confirmed in the paraventricular hypothalamus
(PVH) (Figure 1C). Immunohistochemical analysis revealed
colocalization of AdipoR1 and the leptin receptor in the
ARH of C57BL/6 mice (Figure 1D), but not db/db or Adi-
poR1-knockout mice (Figure S1B; Yamauchi et al., 2007).
Adiponectin was detected in the CSF of C57BL/6 mice
at approximately 1/4000th of its concentration in the
serum; it was also detected in the CSF of adipo/ mice
(Kubota et al., 2002; Kubota et al., 2006) 3 hr after intrave-
nous (i.v.) injection of full-length adiponectin (1 mg/kg) ad-
ministered to raise the serum adiponectin levels in these
mice to approximately the same levels as in wild-type
mice (Figure 1E). These findings indicate that adiponectin
does indeed enter the CSF from the circulation. Adiponec-
tin is known to exist in three forms, namely, trimers, hex-
amers, and HMW multimers, in the serum of wild-type
mice (Figure 1F, left panel). Interestingly, unlike in the se-
rum, only trimers and hexamers, and not HMW multimers,
were found in the CSF of the wild-type mice (Figure 1F,
right panel). In adipo/ mice, at 3 hr after i.v. injection of
full-length adiponectin (1 mg/kg), all three forms, i.e., tri-
mers, hexamers, and HMW multimers, were found in the
serum (Figure 1G, left panel), while only trimers and hex-
amers, and not HMW multimers, were found in the CSF
(Figure 1G, right panel). These data indicate that the distri-
bution of the multimeric forms of adiponectin in the CSF
differs from that in the serum. It should also be noted
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Adiponectin and AMPK in the HypothalamusFigure 1. Adiponectin Receptors Are Present in the Hypothalamus, and Adiponectin Enters the CSF from the Circulation
(A) AdipoR1 and AdipoR2 expression levels in the hypothalamus and liver in C57BL/6 mice (n = 5). In this and all other figures, error bars represent ±SEM.
(B) In situ hybridization for AdipoR1, AdipoR2, and the leptin receptor in brain sections of C57BL/6 mice containing hypothalamic tissue (n = 3). Scale
bar = 1 mm.
(C) AdipoR1 and AdipoR2 expression levels in the arcuate hypothalamus (ARH) and paraventricular hypothalamus (PVH) in C57BL/6 mice (n = 6).
(D) Immunohistochemistry for AdipoR1 and the leptin receptor in the hypothalamus of C57BL/6 mice. Magnification 34 (upper panels); 3400 (lower
panels).
(E) Adiponectin concentration in the serum and CSF of C57BL/6 mice and adipo/mice at 3 hr after intravenous (i.v.) injection of full-length adiponectin
(1 mg/kg) (n = 4).
(F and G) Multimeric forms of adiponectin in the serum and CSF of C57BL/6 and adipo/ mice (F) and adipo/ mice at 3 hr after i.v. injection of
full-length adiponectin (1 mg/kg) (G) (n = 3) as determined by SDS-PAGE under nonreducing and non-heat-denaturing conditions.
(H–J) Adiponectin concentrations in the serum and CSF (H), CSF-to-serum adiponectin ratios (I), and AdiopoR1 and AdipoR2 expression levels in the
ARH (J) in C57BL/6 and ob/ob mice after 12 hr fasting followed by 3 hr refeeding (n = 8–11).
All experiments illustrated in this figure were performed using 11- to 13-week-old male mice. *p < 0.05; **p < 0.01.Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 57
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Adiponectin and AMPK in the HypothalamusFigure 2. Adiponectin Increases AMPK Activity in the ARH and Food Intake via AdipoR1
(A) Serum adiponectin levels at 3 hr after i.v. injection of saline or full-length adiponectin (1 mg/kg) in C57BL/6 mice (n = 5).
(B–F) These experiments were performed according to protocol 1 (Figure S3A). Black bars indicate AMPK and ACC phosphorylation in group 1, gray
bars indicate AMPK and ACC phosphorylation in group 2 administered an i.v. injection of saline, and white bars indicate AMPK and ACC phosphor-
ylation in group 3 administered an i.v. injection of full-length adiponectin (1 mg/kg) (n = 6).
(B) AMPK and ACC phosphorylation in the ARH of C57BL/6 mice.
(C) AMPK and ACC phosphorylation in the ARH of C57BL/6 mice injected with adeno-LacZ or adeno-AdipoR1 siRNA under fasting conditions.
(D) AMPK phosphorylation in the ARH of C57BL/6 mice injected with adeno-LacZ or adeno-AdipoR1 siRNA.
(E) AMPK phosphorylation in the ARH of C57BL/6 mice injected with adeno-LacZ or adeno-AdipoR2 siRNA.
(F) ACC phosphorylation in the ARH of C57BL/6 mice injected with adeno-LacZ, adeno-AdipoR1 siRNA, or adeno-AdipoR2 siRNA.
(G–J) Food intake was measured according to protocol 2 (Figure S3B). Black bars indicate food intake by group 1, gray bars indicate food intake
by group 2 administered an i.v. injection of saline, and white bars indicate food intake by group 3 administered an i.v. injection of full-length
adiponectin (1 mg/kg) (n = 6).58 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.
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nectin found in the CSF (Figure 1G, right panel) were the
same as those of the endogenous adiponectin found in
the CSF of wild-type mice (Figure 1F, right panel).
Serum adiponectin levels in ob/ob mice were signifi-
cantly lower than those in wild-type mice, both under fast-
ing conditions and after refeeding (Figure 1H, left panel). In
wild-type mice, while plasma levels of glucose and insulin
and serum levels of leptin increased significantly after
refeeding (Figures S2A–S2C), serum adiponectin levels
decreased significantly (Figure 1H, left panel). In contrast,
in ob/ob mice, serum adiponectin levels remained un-
changed even after refeeding (Figure 1H, left panel). Unlike
in the serum, CSF adiponectin levels in ob/ob mice were
similar to those in wild-type mice both under fasting condi-
tions and after refeeding (Figure 1H, right panel). However,
while CSF adiponectin levels decreased significantly after
refeeding in wild-type mice (Figure 1H, right panel), the
levels in ob/obmice remained unaltered even after refeed-
ing (Figure 1H, right panel). In addition, the ratios of CSF to
serum adiponectin levels were significantly higher in ob/ob
mice than those in wild-type mice both under fasting con-
ditions and after refeeding (Figure 1I). These findings indi-
cate that, unlike serum adiponectin levels, CSF adiponec-
tin levels, which were relatively higher in ob/ob mice, may
not be correlated with obesity or obesity-linked insulin re-
sistance. In wild-type mice, the expression of AdipoR1 in
the ARH decreased significantly after refeeding, whereas
that of AdipoR2 remained unchanged (Figure 1J). On the
other hand, the expression of both AdipoR1 and AdipoR2
remained unchanged after refeeding in ob/ob mice
(Figure 1J).
Adiponectin Increases AMPK Activity in the ARH via
AdipoR1 to Stimulate Food Intake
In view of the increases in adiponectin concentrations in
the serum and CSF and the increases in the AdipoR1 ex-
pression level in the ARH under fasting conditions, adipo-
nectin signals may be involved in the stimulation of food
intake. It has been suggested that adiponectin is an orexi-
genic hormone and that it may stimulate the phosphoryla-
tion of AMPK and acetyl-CoA carboxylase (ACC), down-
stream of AMPK, in the hypothalamus (Hardie, 2004;
Andersson et al., 2004; Carling, 2005; Xue and Kahn,
2006). To evaluate this effect of adiponectin, wild-typemice were divided into three groups, as follows, after 12
hr fasting during the dark phase of the light/dark cycle (Fig-
ure S3A, protocol 1): group 1, in which the ARH was sam-
pled immediately; group 2, in which the mice were allowed
access to food for the first 3 hr and then administered an
i.v. infusion of saline for 3 hr prior to ARH sampling; and
group 3, in which the mice were allowed access to food
for the first 3 hr and then administered an i.v. injection of
adiponectin, followed 3 hr later by ARH sampling. Serum
adiponectin levels were 2-fold higher 3 hr after adiponectin
injection in group 3 than after saline injection in group 2
(Figure 2A). Phosphorylation of AMPK and ACC was sup-
pressed after refeeding (Figure 2B) (Andersson et al.,
2004; Minokoshi et al., 2004; Xue and Kahn, 2006). Admin-
istration of adiponectin increased the phosphorylation of
threonine 172, which is known to stimulate AMPK activity
(Hardie, 2004; Carling, 2005), of AMPK in group 3 (Fig-
ure 2B). Consistent with this, adiponectin also increased
the phosphorylation of ACC (Figure 2B), which is a down-
stream target of AMPK, although the possible effect of
other signaling pathways on ACC phosphorylation cannot
be entirely excluded.
Next, we investigated whether the enhanced AMPK ac-
tivation by adiponectin was mediated by the adiponectin
receptors expressed in the ARH by injecting adeno-
AdipoR1 siRNA or adeno-AdipoR2 siRNA into the ARH,
using adeno-LacZ as a control. We confirmed that the ad-
enovirus vectors had been successfully injected into the
ARH by the observation of positive LacZ immunostaining
in the region (Figure S4A). The phosphorylation of AMPK
and ACC in the ARH was significantly suppressed in the
adeno-AdipoR1 siRNA-treated mice as compared with the
adeno-LacZ-treated mice under fasting conditions (Fig-
ure 2C). After refeeding, phosphorylation of AMPK and
ACC was also suppressed in the control group treated with
adeno-LacZ, and this was reversed by the administration
of adiponectin (Figures 2D and 2F). However, in the ani-
mals in which AdipoR1 expression in the ARH was de-
creased by treatment with AdipoR1 siRNA (Figures S4B
and S4C), adiponectin failed to reverse the suppression
of AMPK and ACC phosphorylation observed after refeed-
ing (Figures 2D and 2F). On the other hand, when AdipoR2
expression in the ARH was reduced by the administration
of AdipoR2 siRNA (Figure S4D), the suppression of AMPK
and ACC phosphorylation after refeeding was still(G) Food intake by C57BL/6 mice.
(H) Adeno-LacZ or adeno-AdipoR1 siRNA was injected into the ARH of C57BL/6 mice.
(I) Adeno-LacZ or adeno-AdipoR2 siRNA was injected into the ARH of C57BL/6 mice.
(J) Adeno-LacZ or adeno-D/N-AMPK was injected into the ARH of C57BL/6 mice.
(K) Oxygen consumption in fasting C57BL/6 mice injected i.v. with saline or adiponectin (1 mg/kg) (n = 7).
(L) UCP1 expression in brown adipose tissue (BAT) after 12 hr fasting (n = 4–5).
(M) This experiment was performed according to protocol 1 (Figure S3A). Black bars indicate AMPK and ACC phosphorylation in group 1, gray bars
indicate AMPK and ACC phosphorylation in group 2 administered an intracerebroventricular (i.c.v.) injection of PBS, and white bars indicate AMPK
and ACC phosphorylation in group 3 administered an i.c.v. injection of the hexameric form of adiponectin (150 ng) (n = 6).
(N) Food intake was measured according to protocol 2 (Figure S3B). Black bar indicates food intake by group 1, gray bar indicates food intake by
group 2 administered an i.c.v. injection of PBS, and white bar indicates food intake by group 3 administered an i.c.v. injection of the hexameric
form of adiponectin (150 ng) (n = 8).
(O) Oxygen consumption in fasting C57BL/6 mice administered an i.c.v. injection of the hexameric form of adiponectin (150 ng) (n = 7).
All experiments illustrated in this figure were performed using 11- to 13-week-old male mice. *p < 0.05; **p < 0.01.Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 59
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ings suggest that adiponectin directly activates AMPK in
the ARH via AdipoR1, but not AdipoR2.
Since increased AMPK activity in the ARH has been
shown to stimulate food intake (Hardie, 2004; Minokoshi
et al., 2004; Carling, 2005), we then investigated the effect
of adiponectin on food intake. In accordance with the pro-
tocol used to measure the AMPK activity, wild-type mice
were divided into three groups, as follows, after 12 hr fast-
ing during the dark phase of the light/dark cycle, and the
amount of food intake was measured over a period of
6 hr (Figure S3B, protocol 2): group 1, in which the mice
were immediately allowed access to food throughout the
6 hr; group 2, in which the mice were allowed access to
food for 3 hr and then administered an i.v. infusion of
saline, and food intake was measured over the next 6 hr;
and group 3, in which the mice were allowed access to
food for 3 hr and then administered an i.v. injection of adi-
ponectin, and food intake was measured over the next 6
hr. Food intake after refeeding (group 2) (Figure 2G, gray
bar) was significantly lower than after fasting (group 1)
(Figure 2G, black bar), as the AMPK and ACC phosphory-
lation levels decreased (Figure 2B). Adiponectin injection
significantly increased food intake after refeeding (group
3) (Figure 2G, white bar), as the AMPK and ACC phosphor-
ylation levels increased (Figure 2B). In the mice in which
AdipoR1 expression in the ARH was decreased by treat-
ment with AdipoR1 siRNA (Figures S4B and S4C), the
stimulation of food intake by adiponectin injection (Fig-
ure 2H, left, white bar) was blunted (Figure 2H, right, white
bar). On the other hand, in the mice in which AdipoR2
expression in the ARH was decreased by treatment with
AdipoR2 siRNA (Figure S4D), no such blunting of the effect
of adiponectin injection was observed (Figure 2I, right,
white bar). These findings suggest that adiponectin stim-
ulates food intake via AdipoR1 in the ARH.
Next, in order to investigate whether the stimulation of
food intake induced by adiponectin is actually mediated
by AMPK, dominant-negative AMPK (D/N-AMPK) was ex-
pressed in the ARH, and the amount of food intake over
a period of 6 hr was measured according to protocol 2 de-
scribed above (Figure S3B). In the control group treated
with LacZ, the amount of food consumed after adiponec-
tin injection (group 3) (Figure 2J, left, white bar) was signif-
icantly higher than after saline injection (group 2) (Fig-
ure 2J, left, gray bar). In contrast, in the group treated
with D/N-AMPK, the stimulation of food intake by the adi-
ponectin injection (Figure 2J, left, white bar) was blunted
(Figure 2J, right, white bar), suggesting that adiponectin
has a central action of stimulating food intake by activating
AMPK in the ARH. In addition to regulating food intake,
AMPK in the hypothalamus is also thought to regulate en-
ergy expenditure (Hardie, 2004; Carling, 2005; Kim and
Lee, 2005). Examination of the effect of adiponectin on
energy expenditure revealed that oxygen consumption
during the light and dark phases of the 24 hr cycle was sig-
nificantly decreased by adiponectin (Figure 2K). Consis-
tent with these findings, expression of uncoupling protein
1 (UCP1) in brown adipose tissue (BAT) was significantly60 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.decreased at 12 hr after i.v. injection of adiponectin
(Figure 2L).
We then administered the hexameric form of adiponec-
tin (Figure S4E), the predominant form in the CSF (Fig-
ure 1F), directly into the lateral cerebral ventricles and ex-
amined the direct effects of adiponectin in order to rule out
the possibility that the actions of adiponectin on the pe-
ripheral organs participate in the AMPK activation in the
ARH and stimulation of food intake. The suppression of
AMPK and ACC phosphorylation after refeeding was in-
deed reversed by intracerebroventricular (i.c.v.) adminis-
tration of the hexameric form of adiponectin (Figure S3A,
protocol 1) (Figure 2M). i.c.v. injection of the hexameric
form of adiponectin also significantly stimulated food in-
take after refeeding (Figure S3B, protocol 2) (Figure 2N,
white bar), along with increasing the AMPK and ACC
phosphorylation levels (Figure 2M). Moreover, oxygen
consumption during the light and dark phases of the 24
hr cycle was significantly decreased following i.c.v. injec-
tion of the hexameric form of adiponectin (Figure 2O). i.v.
injection of adiponectin decreased energy expenditure
(Figure 2K) and UCP1 expression in BAT (Figure 2L). Since
i.c.v. injection of the hexameric form of adiponectin also
decreased energy expenditure (Figure 2O), determination
of UCP1 expression in BAT following i.c.v. administration
may aid our understanding of the effect of adiponectin in
the CNS. Taken together, these findings indicate that adi-
ponectin directly regulates AMPK activity in the ARH and
food intake.
Adiponectin Reverses Leptin-Induced Suppression
of AMPK Activity in the ARH and Food Intake via
AdipoR1
Because leptin has been reported to inhibit AMPK activity
in the ARH and to thereby suppress food intake (Mino-
koshi et al., 2004), we investigated the effect of adiponec-
tin on the leptin-induced suppression of AMPK activity in
the ARH and food intake. Wild-type mice were divided into
three groups, as follows, after 12 hr fasting during the dark
phase of the light/dark cycle (Figure S3C, protocol 3):
group 1, in which the ARH was sampled 3 hr after an i.v.
injection of saline; group 2, in which the ARH was sampled
3 hr after an i.v. injection of leptin; and group 3, in which
the ARH was sampled 3 hr after an i.v. injection of leptin +
adiponectin. The AMPK and ACC phosphorylation in the
ARH was significantly suppressed following leptin admin-
istration (group 2) (Figure 3A) (Minokoshi et al., 2004; Xue
and Kahn, 2006), but the leptin-induced suppression was
reversed by adiponectin (group 3) (Figure 3A). We then in-
vestigated whether the increase in AMPK activity induced
by adiponectin was mediated by AdipoR1 in the ARH. The
AMPK and ACC phosphorylation in the ARH of the adeno-
AdipoR1 siRNA-treated mice was significantly suppressed
as compared with the LacZ-treated mice under fasting
conditions (Figure 3B), as shown in Figure 2C. In the control
group treated with LacZ, AMPK and ACC phosphoryla-
tion was suppressed by leptin, which was again reversed
by adiponectin (Figures 3C and 3D). When AdipoR1 ex-
pression in the ARH was reduced by injection of AdipoR1
Cell Metabolism
Adiponectin and AMPK in the HypothalamusFigure 3. Adiponectin Reverses Leptin-
Induced Suppression of AMPK Activity
in the ARH and Food Intake via AdipoR1
(A–D) These experiments were performed ac-
cording to protocol 3 (Figure S3C). Black bars
indicate AMPK and ACC phosphorylation in
group 1, gray bars indicate AMPK and ACC
phosphorylation in group 2 administered an
i.v. injection of saline, and white bars indicate
AMPK and ACC phosphorylation in group 3
administered an i.v. injection of full-length
adiponectin (1 mg/kg) (n = 6).
(A) AMPK and ACC phosphorylation in the ARH
of C57BL/6 mice.
(B) AMPK and ACC phosphorylation in the ARH
of C57BL/6 mice following injection of adeno-
LacZ or adeno-AdipoR1 siRNA under fasting
conditions.
(C and D) AMPK (C) and ACC (D) phosphoryla-
tion in the ARH of C57BL/6 mice following
injection of adeno-LacZ or adeno-AdipoR1
siRNA.
(E and F) Food intake was measured according
to protocol 4 (Figure S3D). Black bars indicate
food intake by group 1, gray bars indicate food
intake by group 2 administered an i.v. injection
of saline, and white bars indicate food intake
by group 3 administered an i.v. injection of
full-length adiponectin (n = 6).
(E) Food intake by C57BL/6 mice.
(F) Adeno-LacZ or adeno-AdipoR1 siRNA was
injected into the ARH of C57BL/6 mice.
All experiments illustrated in this figure were
performed using 11- to 13-week-old male
mice. *p < 0.05.siRNA (Figures S4B and S4C), adiponectin failed to reverse
the suppression of AMPK and ACC phosphorylation in-
duced by leptin (Figures 3C and 3D).
In accordance with the protocol used to measure the
AMPK activity, wild-type mice were divided into three
groups, as follows, after 12 hr fasting during the dark
phase of the light/dark cycle, and food intake was mea-
sured over a period of 6 hr (Figure S3D, protocol 4): group
1, in which the mice were administered an i.v. injection of
saline; group 2, in which the mice were administered an
i.v. injection of leptin; and group 3, in which the mice
were administered an i.v. injection of leptin + adiponectin.
We found that adiponectin reversed the suppression of
food intake induced by leptin (Figure 3E). In the animals
in which AdipoR1 expression in the ARH was decreased
by treatment with AdipoR1 siRNA (Figures S4B and S4C),
adiponectin failed to reverse the leptin-induced suppres-
sion of food intake (Figure 3F). These findings suggest
that adiponectin reverses the leptin-induced suppressionof AMPK activity and food intake via its central effects on
AdipoR1.
adipo/ Mice Exhibit Decreased AMPK Activity
in the ARH, Increased Oxygen Consumption,
and Greater Loss of Fat during Fasting
In order to further elucidate the physiological role of adipo-
nectin in the CNS, we investigated the effects of adiponec-
tin deficiency on AMPK activity, food intake, and energy
homeostasis in adipo/ mice. AMPK phosphorylation in
the ARH was significantly suppressed in adipo/ mice
after 12 hr fasting (Figure 4A). Expression of neuropeptide
Y (NPY) in the ARH after 12 hr fasting was also significantly
lower in adipo/ mice (Figure 4B), while the expression of
pro-opiomelanocortin (POMC) in the ARH was increased
after 12 hr fasting in these mice (Figure 4C). Consistent
with the decreased AMPK activity and decreased NPY ex-
pression in the ARH,adipo/mice consumed significantly
more oxygen than their wild-type littermates during theCell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 61
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Adiponectin and AMPK in the HypothalamusFigure 4. adipo/ Mice Exhibit Decreased AMPK Activity in the ARH, Increased Oxygen Consumption, and Greater Loss of Fat
during Fasting
(A) AMPK phosphorylation in the ARH of wild-type and adipo/ mice after 12 hr fasting (n = 6).
(B and C) NPY (B) and POMC (C) expression in the ARH after 12 hr fasting (n = 6).
(D) Oxygen consumption in wild-type and adipo/ mice under fasting conditions (n = 9).
(E) Daily food intake by wild-type and adipo/ mice (n = 9–11).
(F) UCP1 expression in BAT of wild-type and adipo/ mice (n = 6).
(G) AMPK phosphorylation in skeletal muscle of wild-type and adipo/ mice (n = 6).
(H) Body weight (left) and fat mass measured by dual-energy X-ray absorptiometry (right) in wild-type and adipo/ mice (n = 10–11).
(I) Visceral (epididymal, retroperitoneal, andperirenal) and subcutaneous fatmass inwild-type andadipo/micebefore and after 12 hr fasting (n = 4–13).
(J) Serum leptin levels in wild-type and adipo/ mice after 6 hr fasting (n = 13–15).
(K) Decreased food intake and body weight in wild-type and adipo/ mice after intraperitoneal injection of leptin (5 mg/kg) (n = 5–7).62 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.
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Adiponectin and AMPK in the Hypothalamuslight and dark phases of the 24 hr cycle under fasting con-
ditions (Figure 4D), even though food intake remained
unchanged (Figure 4E). Expression of UCP1 in BAT was
significantly increased in adipo/ mice as compared
with wild-type mice (Figure 4F). Moreover, despite the adi-
ponectin deficiency, AMPK phosphorylation in skeletal
muscle was significantly increased in adipo/ mice com-
pared to their wild-type littermates (Figure 4G). These in-
creases in UCP1 expression and AMPK phosphorylation,
which may account for the increased energy expenditure
in adipo/ mice, cannot be explained by the peripheral
actions of adiponectin but may presumably be explainable
by its central actions.
Despite the similarbody weightof wild-type andadipo/
mice (Figure 4H, left), body fat mass, as measured by dual-
energy X-ray absorptiometry (DEXA), was significantly
lower in adipo/ mice than in wild-type mice (Figure 4H,
right) (p < 0.001). The reduction in visceral and subcutane-
ous fat mass after 12 hr fasting was greater in adipo/
mice than in wild-type mice (Figure 4I). Consistent with
these findings, serum leptin levels after 6 hr fasting were
significantly lower in adipo/ mice than in wild-type
mice (Figure 4J). Moreover, the suppression of food intake
(Figure 4K, left) and the weight loss (Figure 4K, right)
induced by intraperitoneal injection of leptin (5 mg/kg)
were significantly greater in adipo/ mice than in wild-
type mice, indicating that adipo/ mice are probably
more leptin sensitive than wild-type mice. To further con-
firm the leptin-sensitive phenotype of adipo/ mice, we
administered leptin for a week at 0.3 mg/hr to wild-type
and adipo/ mice via a subcutaneously implanted os-
motic pump. Leptin infused at this dose failed to produce
any significant decrease in food intake (Figure 4L, upper
left panel) or body weight (Figure 4L, upper right panel)
in wild-type mice. In contrast, the same dose of leptin sig-
nificantly decreased both food intake (Figure 4L, lower left
panel) and body weight (Figure 4L, lower right panel) in
adipo/ mice. These data confirm the higher leptin sensi-
tivity of adipo/ mice as compared with wild-type mice.
adipo/ Mice Exhibit Reduced Food Intake
and Increased Oxygen Consumption and Appear
to Be Protected from High-Fat-Diet-Induced Obesity
adipo/ mice were found to be more resistant to HFD-
induced obesity than wild-type mice (Figure 5A). The vis-
ceral WAT mass and subcutaneous WAT mass were
both significantly smaller in adipo/ mice fed a HFD (Fig-
ure 5B). Histological analysis of WAT and quantitation of
adipocyte size in the mice revealed significantly smaller
adipocytes in adipo/ mice than in wild-type mice (Fig-
ure 5C). Additionally, after 2 weeks of HFD, when the
two groups were indistinguishable by body weight, we
examined serum leptin levels, AMPK and ACC phosphor-
ylation status, AdipoR1 and AdipoR2 expression, food in-
take, and oxygen consumption in the two groups. Serumleptin levels after 6 hr fasting were significantly lower in
adipo/ mice than in wild-type mice (Figure 5D). AMPK
and ACC phosphorylation in the ARH was significantly
suppressed in adipo/ mice after 12 hr fasting
(Figure 4E), although the expression levels of AdipoR1
and AdipoR2 in the ARH were not significantly different
between the two genotypes (Figure 5F). Daily food intake
was significantly lower in adipo/ mice than in wild-type
mice (Figure 5G), and oxygen consumption was signifi-
cantly greater (Figure 5H).
DISCUSSION
In this study, we demonstrate that adiponectin activates
AMPK via AdipoR1 in the hypothalamus, leading to stimu-
lation of food intake and decrease in energy expenditure.
Consistent with these findings, adipo/ mice fed a HFD
exhibit decreased AMPK phosphorylation and NPY ex-
pression in the ARH, reduced food intake, and increased
energy expenditure, thereby exhibiting resistance to
HFD-induced obesity. Scherer’s group (Kim et al., 2007)
has generated adiponectin-transgenic ob/ob mice that
show serum adiponectin levels 3- to 4-fold higher than
ob/ob mice. These mice also show markedly increased
body weight due to decreased energy expenditure, as
manifested by lower body temperature and lower oxygen
consumption, consistent with our observations that adi-
ponectin decreases energy expenditure (Figures 2K and
2O) and UCP1 expression in BAT (Figure 2L) and that
adipo/ mice exhibit increased oxygen consumption
(Figure 4D and Figure 5H). We also found that serum
and CSF adiponectin levels and expression of AdipoR1
in the ARH increase during fasting and decrease after re-
feeding, suggesting that adiponectin acts mainly under
fasting conditions. Moreover, the reduction of visceral
and subcutaneous fat mass that was observed after 12
hr fasting was greater in adipo/ mice than in wild-type
mice (Figure 4I). Based on these results, we propose
that adiponectin serves as a starvation hormone that facil-
itates efficient fat storage in WAT under fasting conditions.
The blood-CSF barrier in the choroid plexus and the
BBB in the cerebral endothelium are the two major sites
controlling the entry of proteins into the brain (Zlokovic
et al., 2000; Schwartz and Porte, 2005). The relative contri-
butions of these two CNS transport pathways in maintain-
ing adiponectin homeostasis in the CNS and the access
pathway of adiponectin to the hypothalamus and/or other
CNS targets are unknown. Nevertheless, in this study, adi-
ponectin was shown to be present in the CSF and to enter
the CSF from the circulation (Figures 1E–1G), as described
by Ahima’s group (Qi et al., 2004). Furthermore, the adipo-
nectin receptors adipoR1 and adipoR2 were found to be
expressed in the hypothalamus (Figures 1A–1D) and BBB
endothelial cells (Spranger et al., 2006). We speculate that
an adiponectin transport system mediated by adiponectin(L) Food intake and body weight in wild-type and adipo/ mice implanted with a subcutaneous osmotic minipump to deliver saline or 0.3 mg/hr leptin.
(n = 6–9).
All experiments illustrated in this figure were performed using 9- to 13-week-old male mice. *p < 0.05; **p < 0.01; ***p < 0.001.Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 63
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creased Food Intake and Increased
Oxygen Consumption and Are Protected
from High-Fat-Diet-Induced Obesity
(A) Body weight of wild-type and adipo/ mice
on a high-fat diet (HFD) (n = 21–24).
(B) Weight of visceral (epididymal, retroperito-
neal, and perirenal) and subcutaneous fat
pads after 20 weeks on HFD (n = 21–24).
(C) Histological analysis of white adipose tissue
(left panels) and quantitation of adipocyte size
(right panel) in wild-type and adipo/ mice
after 20 weeks on HFD (n = 7–8). Magnifica-
tion 3100.
(D) Serum leptin levels after 6 hr fasting in wild-
type and adipo/ mice fed a HFD for 2 weeks
(n = 6).
(E) AMPK and ACC phosphorylation after 6 hr
fasting in the ARH of wild-type and adipo/
mice fed a HFD for 2 weeks (n = 6).
(F) AdipoR1 and AdipoR2 expression levels in
the ARH and PVH of wild-type and adipo/
mice before and after administration of a HFD
for 2 weeks (n = 5–8).
(G) Food intake by wild-type and adipo/ mice
after administration of a HFD for 2 weeks (n = 9).
(H) Oxygen consumption under fasting condi-
tions in wild-type and adipo/ mice after ad-
ministration of a HFD for 2 weeks (n = 9).
*p < 0.05; **p < 0.01.receptors in the hypothalamus and choroid plexus may
regulate adiponectin entry into the CNS and CSF under
physiological conditions. Further investigation is needed
to verify this contention.
Although the HMW form of adiponectin is believed to be
more closely associated with insulin sensitivity and is con-
sidered to be a relatively more metabolically active form
than the trimeric and hexameric forms of adiponectin, it
must be borne in mind that all three forms can bind to
AdipoR1 and activate AMPK (Kadowaki, et al., 2006;
Hada, et al., 2007). Interestingly, while the trimers, hexam-
ers, and HMW multimers of adiponectin were found in the
serum, only the trimer and hexamer forms were found in
the CSF. Since HMW adiponectin consists of a large num-64 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.ber of complexes, it may be too large to enter the CSF,
which could explain the absence of HMW adiponectin in
the CSF. The trimer and hexamer forms may be responsi-
ble for the central actions of adiponectin under physiolog-
ical conditions. Similar to our findings, a previous study
also reported finding trimers and hexamers of adiponec-
tin, but not HMW multimers, in the human CSF (Kusminski,
et al., 2007).
Why was there no effect of adiponectin deficiency on
food intake in adipo/ mice under normal diet condi-
tions? Considering the increase in oxygen consumption
observed in adipo/ mice, one possibility is that a com-
pensatory increase in the orexigenic pathway may con-
tribute to the maintenance of food intake, thus preventing
Cell Metabolism
Adiponectin and AMPK in the Hypothalamusthese mice from experiencing excessive weight loss. On
the other hand, under conditions of excess energy avail-
ability, such as in animals fed a HFD, this compensation
by the increased orexigenic pathway may disappear. In
fact, food intake was indeed decreased in adipo/ mice
fed a HFD (Figure 5G).
It has been reported that while adiponectin adminis-
tered by i.c.v. injection induces increased oxygen con-
sumption and weight loss, it has no effect on the food
intake (Qi et al., 2004). Our data, however, indicate that
i.v. injection of full-length adiponectin or i.c.v. injection of
the hexameric form of adiponectin (the predominant form
in the CSF) (Figure 1F) significantly stimulates food intake
during refeeding (Figures 2G and 2N) and decreases oxy-
gen consumption (Figures 2K and 2O), although body
weight remained largely unchanged.
Serum levels of adiponectin have been known to be cor-
related inversely with obesity, insulin resistance, and dia-
betes; however, the ob/obmice in this study failed to show
any significant decrease in CSF adiponectin levels as
compared with wild-type mice. In fact, the ob/ob mice
exhibited relatively higher concentrations of adiponectin
in the CSF (Figure 1I). This may indicate a lack of correla-
tion between CSF adiponectin levels and obesity or obe-
sity-linked insulin resistance. Recent studies have shown
that adiponectin exists in human CSF at a concentration
1/1000th of that in serum (Kusminski et al., 2007; Kos
et al., 2007). These data also show that there may be no
association between CSF concentrations of adiponectin
and obesity or insulin resistance except in obese males,
which is in accordance with our findings. Thus, adiponec-
tin may play an important role in the hypothalamus not
only in mouse models but also in humans.
Based on these findings, we propose a hypothesis on
the role of adiponectin in the regulation of food intake
and energy homeostasis (Figure 6). Under fasting condi-
tions, serum and CSF adiponectin levels and AdipoR1 ex-
pression in the ARH increase; consequently, hypothalamic
AMPK is activated, which stimulates food intake and sup-
presses energy expenditure, promoting fat storage. After
refeeding, on the other hand, serum and CSF adiponectin
levels and AdipoR1 expression in the ARH decrease; con-
sequently, hypothalamic AMPK activity decreases, result-
ing in reduced food intake and increased energy expendi-
ture. Serum leptin levels are regulated inversely in relation
to serum adiponectin levels both under fasting conditions
and after refeeding. Leptin suppresses hypothalamic
AMPK activity and food intake, as opposed to the action
of adiponectin. Thus, central adiponectin/leptin signals
may represent the physiological pathway by which hypo-
thalamic AMPK activity and food intake are stimulated
during fasting and suppressed after refeeding.
In addition to this short-term regulation of food intake
and energy expenditure by adiponectin and leptin, these
two adipokines may also participate in the long-term reg-
ulation of energy homeostasis. The fundamental roles of
leptin and adiponectin seem to be to preserve an ade-
quate fat reserve: leptin acts as a satiety signal, and adipo-
nectin acts as a starvation signal. During the course ofevolution, starvation signals are essential for the survival
of an organism, whereas satiety signals develop later as
a complementary system in periods of occasional exces-
sive food intake and fat storage. This may explain why, un-
like the leptin receptor, the adiponectin receptor homolog
has been conserved from yeast to humans (Karpichev
et al., 2002).
In summary, we propose a role for adiponectin in the
regulation of AMPK activity in the hypothalamus, food
intake, and energy expenditure. Our data also suggest
that selective hypothalamic AdipoR1 antagonism may
represent a novel therapeutic strategy for obesity and
obesity-linked diseases.
Figure 6. Adiponectin Regulates Food Intake and Energy
Homeostasis
Under fasting conditions, serum and CSF adiponectin levels and
AdipoR1 expression in the ARH increase; consequently, hypothalamic
AMPK is activated, which stimulates food intake and suppresses
energy expenditure, promoting fat storage. After refeeding, on the
other hand, serum and CSF adiponectin levels and AdipoR1 expres-
sion in the ARH decrease; consequently, hypothalamic AMPK activity
decreases, resulting in reduced food intake and increased energy
expenditure. Serum leptin levels are regulated inversely in relation to
serum adiponectin levels both under fasting conditions and after re-
feeding. Leptin suppresses hypothalamic AMPK activity and food
intake, as opposed to the action of adiponectin. Thus, central adipo-
nectin/leptin signals may represent the physiological pathway by
which hypothalamic AMPK activity and food intake are stimulated
under fasting conditions and suppressed by refeeding.Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc. 65
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Animals
Original adipo/ mice (C57BL/6 and 129/Sv mixed background)
(Kubota et al., 2002) were backcrossed with C57BL/6 mice more
than seven times (Kubota et al., 2006). The mice were housed under
a 12 hr light/dark cycle and given ad libitum access to food. Fasting,
when needed, was started at the end of a light phase of the light/
dark cycle. All experiments in this study were performed on male mice.
Standard and HF (HF-32) diets were purchased from CLEA Japan, Inc.
Long-term cannulae were implanted bilaterally into the ARH in desig-
nated groups of mice 7 days before the experiments were begun.
Based on Franklin and Paxinos (1997), the stereotaxic coordinates for
the intrahypothalamic injections were: anterior/posterior axis, 1.60 mm
posterior to the bregma; lateral, ±0.5 mm from the midline; depth,
5.90 mm from the surface of the skull. Adenovirus vector (0.1 ml)
expressing AdipoR1 siRNA (2.53 107 pfu/0.1 ml) (see below), AdipoR2
siRNA (2.5 3 107 pfu/0.1 ml) (see below), or D/N-AMPK (2.5 3 106
pfu/0.1 ml) (Minokoshi et al., 2004) was injected into the ARH bilater-
ally through the implanted cannulae. The control group was injected
with adenovirus expressing LacZ (2.5 3 107 pfu/0.1 ml) (Yamauchi
et al., 2003). Simultaneously, a catheter was inserted into the right
jugular vein of all mice (see below). Body weight and food intake of
all mice were monitored daily after the injections until completion of
the experiments. Seven days after the injection of the adenovirus vec-
tor, saline, leptin (5 mg/kg), adiponectin (1 mg/kg), or leptin + adipo-
nectin were administered via the catheter both under fasting condi-
tions and after refeeding. In some groups (protocols 2 and 4), food
intake was measured for 6 hr (Figures S3B and S3D), while in other
groups (protocols 1 and 3), the animals were decapitated for sam-
pling at 3 hr after the injections (Figures S3A and S3C). The ARH
was quickly dissected from the first 1 mm-thick midline sagittal sec-
tion of the brain, as described previously (Minokoshi et al., 2004), and
frozen in liquid nitrogen. All animal care and experimental procedures
conformed to the guidelines of the Animal Care Committee of the
University of Tokyo.
Western Blot Analysis and Measurement of AMPK
and ACC Phosphorylation
Tissues were excised and homogenized in ice-cold buffer A (25 mM
Tris-HCl [pH 7.4], 10 mM sodium orthovanadate, 10 mM sodium pyro-
phosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM EGTA, and
1 mM phenylmethylsulfonyl fluoride [PMSF]). The sample buffer for
analysis under reducing conditions was composed of 3% SDS,
50 mM Tris-HCl (pH 6.8), 5% 2-mercaptoethanol, and 10% glycerol.
Samples were mixed with 53 sample buffer, heated at 95C for
5 min for heat denaturation, and then separated on polyacrylamide
gels and transferred to a Hybond-P PVDF transfer membrane (Amer-
sham Biosciences). Bands were detected with ECL detection reagents
(Amersham Biosciences). For analysis under nonreducing conditions,
2-mercaptoethanol was excluded from the sample buffer described
above. Serum samples were diluted 20-fold, while the CSF samples
(2 ml) were used undiluted. Anti-mouse adiponectin antiserum was ob-
tained by immunizing rabbits with mouse recombinant adiponectin
globular domain produced in E. coli (Yamauchi et al., 2001). To detect
the phosphorylation status of a2AMPK, lysates from the ARH (40–50
mg of protein) were immunoprecipitated with anti-phospho-AMPK
(Cell Signaling Technology, Inc.) and blotted with an anti-a2AMPK an-
tibody (Abgent). Lysates from the ARH (5–10 mg of protein) were blot-
ted with anti-AMPK antibody (Cell Signaling Technology, Inc.) as a con-
trol. To detect the phosphorylation status of AMPK in skeletal muscle,
lysates (20 mg of protein) were blotted with anti-phospho-AMPK (Cell
Signaling Technology, Inc.) or with anti-AMPK (Cell Signaling Technol-
ogy, Inc.) antibody as a control. To detect the phosphorylation status
of ACC, lysates from the ARH (5–10 mg of protein) were blotted with
anti-phospho-ACC (Upstate Biotechnology, Inc.) or with anti-ACC
(Upstate Biotechnology, Inc.) antibody as a control. The AMPK and
ACC phosphorylation data were normalized to the AMPK and ACC66 Cell Metabolism 6, 55–68, July 2007 ª2007 Elsevier Inc.levels and calculated as the fold intensity relative to the baseline value
and are representative of three independent experiments.
Generation of cRNA Probes and In Situ Hybridization
PCR products were ligated to the vector with a TA cloning kit (Invitro-
gen). 35S-labeled riboprobes were generated from fragments of the
PCR products for AdipoR1, AdipoR2, and the leptin receptor using
a transcription kit according to the manufacturer’s instructions (Boeh-
ringer Mannheim). Antisense probes for AdipoR1, AdipoR2, and the
leptin receptor were generated using T3, T7, and Sp6 polymerases, re-
spectively, and sense probes for all three were generated with Sp6/T7
polymerase (Ueta et al., 1995). Frozen 12 mm-thick mouse brain sec-
tions containing the hypothalamus were fixed in 4% formaldehyde; de-
hydrated by sequential transfer through 70%, 80%, 95%, and 100%
ethanol; and delipidated in 100% chloroform for 5 min. The slides
were hybridized with 35S-labeled antisense and sense probes under
Nescofilm coverslips, and the films were exposed for 3–8 days (Ueta
et al., 1995). The data shown are representative of three independent
experiments. White indicates the most intense signal, and black indi-
cates the least intense signal.
Histological Analysis of WAT and Determination
of Adipocyte Size
WAT was immediately immersion fixed overnight in Bouin’s solution at
4C. Tissues were routinely processed for paraffin embedding, and
2 mm sections were cut and mounted on silanized slides. The sections
were stained with hematoxylin and eosin. The total area occupied by
adipocytes was traced manually and analyzed with Win ROOF soft-
ware (Mitani Co., Ltd.). The sizes of 200 or more white adipocytes
per mouse in each group were determined as described previously
(Kubota et al., 1999).
Generation of Adenoviral RNAi Constructs
The sequences of the sense siRNAs used were: mouse AdipoR1, 50-
AGACCAAATATGTACTTCATG-30; mouse AdipoR2, 50-CCCGACTCT
TCTCTAAATTG-30. An adenovirus vector expressing siRNA against
AdipoR1 was constructed as described previously (Yamauchi et al.,
2003), with minor modifications. The E1 and E3 regions of the circular
form of adenoviral DNA were replaced with a cosmid vector flanked by
FRT sites, designated as pAFC. The U6 promoter combined with the
RNAi sequence and a loop sequence (TTCAAGAGA) was inserted
into the SwaI site of pAFC between the FRT-flanked cosmid backbone
and the adenoviral genome (Yamauchi et al., 2003). Cotransfection of
an FLP expression plasmid with this cosmid into 293 cells efficiently
excised the FRT-flanked cosmid vector backbone and produced an
adenovirus vector expressing siRNA against AdipoR1 or AdipoR2.
Prior to in vivo use, all adenovirus vectors were purified on a cesium
chloride gradient and dialyzed with PBS plus 10% glycerol.
Immunohistochemistry for AdipoR1 and the Leptin
Receptor in the Hypothalamus
AdipoR1 and the leptin receptor were visualized by immunohistochem-
ical analysis in the hypothalamus. After PBS equilibration, 20 mm-thick
frozen sections of hypothalamus were incubated with 3% normal goat
serum in 2.5% Triton X-100/PBS as the blocking solution for 2 hr at
room temperature. Simultaneous incubation with both primary anti-
rabbit AdipoR1 antibody and anti-rat leptin receptor antibody diluted
1:100 was performed in blocking solution overnight at 4C. After six
washes with PBS, the slides were simultaneously incubated with
both anti-rabbit IgG:Alexa Fluor 488 and anti-rat IgG:Alexa Fluor 546
(Molecular Probes) in blocking solution for 2 hr at room temperature.
DAPI staining (1:200 dilution) was performed at room temperature for
5min. After a final rinse with PBS, the sections were mounted witha Pro-
Long Antifade kit (Molecular Probes) and examined under a fluores-
cence microscope (BZ-8000, Keyence) (Kondo et al., 2003).
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Data are expressed as ±SEM. Student’s t test was used for statistical
analysis of the differences between two groups, and the statistical sig-
nificance of differences among multiple groups was determined by
ANOVA and Tukey’s t test.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and four figures and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/6/1/55/DC1/.
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